Search research articles
Contact Us
Filters
Showing results (191-200 of 418) with videos related to
Page
of 42
Sort By:
The Journal of Pathology
|
May 30, 2013
Parallel evolution of tumour subclones mimics diversity between tumours
Pierre Martinez, Nicolai Juul Birkbak, Marco Gerlinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2014
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel
Nicholas Coupe, Pippa Corrie, Mirela Hategan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib
Karl Lewis, Axel Hauschild, James Larkin, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|
January 30, 2026
Sustainable kidney care: A life cycle assessment of the peritoneal dialysis pathways
James Larkin, Giulia Ligabue, Gaetano Alfano, et al.
Exploratory Research in Clinical and Social Pharmacy
|
February 19, 2025
Out-of-pocket prescription medicine expenditure amongst community-dwelling adults: Findings from the Irish longitudinal study on ageing (TILDA) in 2016
James Larkin, Ciaran Prendergast, Logan T Murry, et al.
Cancer Treatment Reviews
|
September 27, 2025
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review
Natalie Charnley, Kate Fife, Daniel Y C Heng, et al.
JAMA Oncology
|
August 4, 2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials
Axel Hauschild, James Larkin, Antoni Ribas, et al.
Research in Social & Administrative Pharmacy : RSAP
|
May 28, 2025
Modelling the impact of changes to prescription medicine cost-sharing schemes among middle aged and older adults
James Larkin, Ciaran Prendergast, Logan T Murry, et al.
Investigational New Drugs
|
August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
Simon Pacey, Martin Gore, David Chao, et al.
Journal of Nephrology
|
September 15, 2025
A life cycle assessment of peritoneal dialysis procurement in Italy: environmental burden and opportunities for improvement
James Larkin, Giulia Ligabue, Gaetano Alfano, et al.
Page
of 42
Search research articles
Search
Showing results (191-200 of 418) with videos related to
Sort By:
Page
of 42
The Journal of Pathology
|
May 30, 2013
Parallel evolution of tumour subclones mimics diversity between tumours
Pierre Martinez, Nicolai Juul Birkbak, Marco Gerlinger, et al.
European Journal of Cancer (Oxford, England : 1990)
|
December 28, 2014
PACMEL: a phase 1 dose escalation trial of trametinib (GSK1120212) in combination with paclitaxel
Nicholas Coupe, Pippa Corrie, Mirela Hategan, et al.
European Journal of Cancer (Oxford, England : 1990)
|
June 8, 2019
Effect of concomitant dosing with acid-reducing agents and vemurafenib dose on survival in patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma treated with vemurafenib ± cobimetinib
Karl Lewis, Axel Hauschild, James Larkin, et al.
Peritoneal Dialysis International : Journal of the International Society for Peritoneal Dialysis
|
January 30, 2026
Sustainable kidney care: A life cycle assessment of the peritoneal dialysis pathways
James Larkin, Giulia Ligabue, Gaetano Alfano, et al.
Exploratory Research in Clinical and Social Pharmacy
|
February 19, 2025
Out-of-pocket prescription medicine expenditure amongst community-dwelling adults: Findings from the Irish longitudinal study on ageing (TILDA) in 2016
James Larkin, Ciaran Prendergast, Logan T Murry, et al.
Cancer Treatment Reviews
|
September 27, 2025
Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review
Natalie Charnley, Kate Fife, Daniel Y C Heng, et al.
JAMA Oncology
|
August 4, 2018
Modeled Prognostic Subgroups for Survival and Treatment Outcomes in BRAF V600-Mutated Metastatic Melanoma: Pooled Analysis of 4 Randomized Clinical Trials
Axel Hauschild, James Larkin, Antoni Ribas, et al.
Research in Social & Administrative Pharmacy : RSAP
|
May 28, 2025
Modelling the impact of changes to prescription medicine cost-sharing schemes among middle aged and older adults
James Larkin, Ciaran Prendergast, Logan T Murry, et al.
Investigational New Drugs
|
August 5, 2010
A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma
Simon Pacey, Martin Gore, David Chao, et al.
Journal of Nephrology
|
September 15, 2025
A life cycle assessment of peritoneal dialysis procurement in Italy: environmental burden and opportunities for improvement
James Larkin, Giulia Ligabue, Gaetano Alfano, et al.
Page
of 42